At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GLUE Monte Rosa Therapeutics
Market Closed 09-11 16:00:00 EDT
14.07
-0.25
-1.75%
盘后14.07
+0.000.00%
19:39 EDT
High14.74Low13.88Vol1.17M
Open14.24D1 Closing14.32Amplitude6.01%
Mkt Cap1.20BTradable Cap766.48MTotal Shares85.31M
T/O16.59MT/O Rate2.15%Tradable Shares54.48M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Monte Rosa Therapeutics Price Target Maintained with a $27.00/Share by Wedbush
Dow Jones  ·  09-09
Monte Rosa Therapeutics Price Target Maintained with a $27.00/Share by Wedbush
Novartis-Backed MRT-6160 Expansion and Strong Partnership Economics Underpin Oliver McCammon’s Buy Rating on Monte Rosa’s GLUE
TIPRANKS  ·  09-09
Novartis-Backed MRT-6160 Expansion and Strong Partnership Economics Underpin Oliver McCammon’s Buy Rating on Monte Rosa’s GLUE
Top Midday Stories: GE Aerospace to Acquire Consolidated Precision Products; Qualcomm Issues Share Warrant to Amazon
MT Newswires Live  ·  09-08
Top Midday Stories: GE Aerospace to Acquire Consolidated Precision Products; Qualcomm Issues Share Warrant to Amazon
Monte Rosa Therapeutics to receive $50M milestone payment from Novartis
TIPRANKS  ·  09-08
Monte Rosa Therapeutics to receive $50M milestone payment from Novartis
Monte Rosa Says Novartis Starts Phase 2 Trial of MRT-6160 in Sjögren's Disease, Triggers USD 50 Million Milestone
Reuters  ·  09-08
Monte Rosa Says Novartis Starts Phase 2 Trial of MRT-6160 in Sjögren's Disease, Triggers USD 50 Million Milestone
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for Vav1-Directed Molecular Glue Degrader Mrt-6160 (Ddy391)
THOMSON REUTERS  ·  09-08
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for Vav1-Directed Molecular Glue Degrader Mrt-6160 (Ddy391)
Monte Rosa Therapeutics, - Eligible for Tiered Royalties on Ex-U.S. Net Sales of Mrt-6160
THOMSON REUTERS  ·  09-08
Monte Rosa Therapeutics, - Eligible for Tiered Royalties on Ex-U.S. Net Sales of Mrt-6160
Monte Rosa Therapeutics, - Novartis to Fund Phase 2; Monte Rosa to Co-Fund Phase 3 and Share 30% U.S. Profits/Losses
THOMSON REUTERS  ·  09-08
Monte Rosa Therapeutics, - Novartis to Fund Phase 2; Monte Rosa to Co-Fund Phase 3 and Share 30% U.S. Profits/Losses
Monte Rosa Therapeutics, - Eligible for up to $2.10 Bln in Milestones Starting with Phase 2 Initiation
THOMSON REUTERS  ·  09-08
Monte Rosa Therapeutics, - Eligible for up to $2.10 Bln in Milestones Starting with Phase 2 Initiation
Monte Rosa Therapeutics, - to Receive $50 Mln Milestone Payment from Novartis for First Patient Visit
THOMSON REUTERS  ·  09-08
Monte Rosa Therapeutics, - to Receive $50 Mln Milestone Payment from Novartis for First Patient Visit
Monte Rosa Grants Inducement Awards to New Hires, Including Options Priced at $14.31
Reuters  ·  09-03
Monte Rosa Grants Inducement Awards to New Hires, Including Options Priced at $14.31
Monte Rosa Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  09-03
Monte Rosa Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Monte Rosa Therapeutics to Present at Wells Fargo Healthcare Conference Fireside Chat
Reuters  ·  09-01
Monte Rosa Therapeutics to Present at Wells Fargo Healthcare Conference Fireside Chat
Monte Rosa Therapeutics (GLUE) Looks Pricey As Phase 2 Progress Keeps The Story Alive
Simply Wall St.  ·  08-26
Monte Rosa Therapeutics (GLUE) Looks Pricey As Phase 2 Progress Keeps The Story Alive
Monte Rosa Therapeutics Price Target Maintained with a $28.00/Share by Guggenheim
Dow Jones  ·  08-25
Monte Rosa Therapeutics Price Target Maintained with a $28.00/Share by Guggenheim
Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Rhythm Pharmaceuticals (RYTM)
TIPRANKS  ·  08-25
Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Rhythm Pharmaceuticals (RYTM)
Monte Rosa Doses First Patient in Phase 2 MODeFIRe-1 Trial of MRT-2359 Plus Apalutamide in mCRPC
Reuters  ·  08-24
Monte Rosa Doses First Patient in Phase 2 MODeFIRe-1 Trial of MRT-2359 Plus Apalutamide in mCRPC
Monte Rosa Therapeutics Announces First Patient Dosed in Modefire-1, a Phase 2 Study of Mrt-2359 in Combination with Apalutamide in Patients with Ar Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
THOMSON REUTERS  ·  08-24
Monte Rosa Therapeutics Announces First Patient Dosed in Modefire-1, a Phase 2 Study of Mrt-2359 in Combination with Apalutamide in Patients with Ar Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
Monte Rosa Therapeutics - to Provide Phase 1/2 Study Update on Mrt-2359 Plus Enzalutamide by Year-End
THOMSON REUTERS  ·  08-24
Monte Rosa Therapeutics - to Provide Phase 1/2 Study Update on Mrt-2359 Plus Enzalutamide by Year-End
Widening Losses And Profitability Swing Might Change The Case For Investing In Monte Rosa Therapeutics (GLUE)
Simply Wall St.  ·  08-17
Widening Losses And Profitability Swing Might Change The Case For Investing In Monte Rosa Therapeutics (GLUE)

Introduction

Company Name.
Monte Rosa Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Issue price:
--